Myostatin Blood Test: Where to Get One and What the Result Means

The test exists. Several of them, in fact. The harder question is what the number actually tells you about your muscle.

Myostatin blood test options at a glance

The market is small but real. Three main test types exist, and they answer different questions.

That table is the whole landscape today. There is no Quest or Labcorp consumer-facing myostatin ELISA, and standing orders for myostatin are unusual outside research clinics.

For why anyone might care about this protein at all, start with the myostatin protein primer. For age-related context, see myostatin and sarcopenia.

What a myostatin blood test actually measures

It measures GDF-8 protein. Myostatin is officially called growth differentiation factor 8 (GDF-8), a member of the TGF-beta superfamily made mainly by skeletal muscle.

In blood, myostatin exists in two main forms. The active "free" myostatin is the cleaved, ligand-ready protein that binds the activin type IIB receptor. The "latent" form circulates bound to its own propeptide and to other binding proteins like follistatin and FSTL3.

Most commercial assays use a sandwich ELISA. Two monoclonal antibodies bind different regions of myostatin, and one is conjugated to a detection signal. Some assays add an acid-dissociation step that strips the propeptide and lets the test read total myostatin instead of just the free fraction.

The widely cited Quantikine GDF-8 ELISA from R&D Systems has a minimum detection limit around 2.25 pg/mL and is the workhorse of clinical studies. Many at-home kits use related sandwich ELISA technology but report in their own units and reference ranges.

That fragmentation is the single biggest reason you cannot compare a result from one kit directly to a result from another.

Free versus total versus ratio

It is not a small distinction. Free myostatin is what actually signals to the receptor. Total myostatin includes the inactive pool that has not yet been cleaved or released from its binding partners.

In aging adults, total myostatin can stay flat while free myostatin climbs. In kidney disease, total myostatin can climb because clearance falls. In response to training, free myostatin tends to drop faster than total.

The follistatin-to-myostatin ratio gets closer to a useful read. Follistatin binds myostatin and reduces its receptor signaling. A higher ratio suggests a more favourable muscle-growth environment, which is why Physicians Lab built the ratio directly into its at-home report.

That is the same logic behind the human epicatechin pilot study, where the ratio rose roughly 49 percent after seven days even when absolute myostatin barely moved. For that story, read epicatechin and myostatin.

Cross-reactivity with GDF-11

This is the technical weakness of the category. Myostatin (GDF-8) and GDF-11 share about 90 percent amino acid identity in their mature signaling domains.

Many older immunoassays cross-react with GDF-11 to varying degrees. ActRIIB-based pull-down assays cannot tell them apart at all. Even modern sandwich ELISAs vary in specificity depending on which antibody clones they use.

The practical consequence is simple. A "high myostatin" result on a less specific assay may partially reflect GDF-11 activity, which has its own biology around aging and metabolism. A 2015 Skeletal Muscle paper by Bergen and colleagues used mass spectrometry instead of antibodies and showed that some classic conclusions about myostatin and aging needed revisiting.

If you are spending $200 on a test, the assay's GDF-11 specificity is worth asking the lab about.

Normal ranges and why they are shaky

The honest answer is that there is no single normal range. Published averages in healthy adults cluster between roughly 1 and 6 ng/mL, but every cohort reports a slightly different number.

Vitamin D status, season of sampling, smoking, BMI, training load, and recent food intake all change the value. So does sex: many studies show myostatin tracks muscle wasting more cleanly in women than in men.

That is why a single number is not enough. Trends over time on the same assay, with the same prep and ideally the same time of day, are more useful than one snapshot.

Available testing options compared

The consumer-facing market has narrowed to two main players and a handful of clinician-ordered options.

Physicians Lab Myostatin and Follistatin Test

Launched in March 2024 from Boca Raton, Florida. The test measures both myostatin and follistatin and reports the ratio.

The sample is a fingerprick dried blood spot collected at home. The lab uses high-sensitivity ELISA. The headline pitch is for adults on GLP-1 agonists like semaglutide, where up to 40 percent of weight loss can come from lean tissue, including muscle.

This is currently the cleanest at-home option for the ratio, and it is the one most often referenced by clinicians who follow muscle-quality markers.

BodyLogic Labs Myostatin Test

Marketed as the first at-home myostatin test on the market. Sample collection is a dried blood spot.

The reporting is simpler than Physicians Lab. The test focuses on myostatin protein levels rather than building out the follistatin-to-myostatin ratio. Price is lower for a single analyte.

BPS Bioscience Assay Services

Not a consumer test. BPS offers custom myostatin assay services to pharma and academic labs, including a TGFB-Activin-Myostatin-responsive luciferase reporter HEK293 cell line.

You would never order this for personal tracking, but it is the back end behind many published myostatin inhibitor studies.

Fulgent Genetics MSTN Single Gene Test

A DNA test, not a protein test. Fulgent's next-generation sequencing assay reads the entire MSTN gene with coverage at or above 99 percent at 20x, plus optional deletion and duplication analysis.

Specimen options are two 4-mL EDTA tubes of blood, extracted DNA, a buccal swab, or saliva. Turnaround is 2 to 3 weeks. CPT code 81479 is billed, and the cash price is provided by quote.

This test answers a different question: are you a carrier of a pathogenic MSTN variant. It does not measure circulating protein.

PlexusDx Precision Peptide Genetic Test

A direct-to-consumer panel that includes MSTN plus 14 other muscle-related genes (ACTN3, IGF1, GHSR, GHR, VDR, ACE, IL-6, and others). Sample is a cheek swab.

Useful for general curiosity about hypertrophy ceiling. Less useful clinically than the Fulgent single-gene assay when there is a real suspicion of a pathogenic variant.

For more on the gene side, see the CRISPR myostatin overview and myostatin deficiency in humans.

How to interpret a high or low result

The interpretation is not symmetrical. High and low results mean different things, and both need context.

A high myostatin result is the more common reason to test. It can reflect aging, kidney or liver disease, heart failure, cancer cachexia, sarcopenic obesity, or simply a low-training period. It is not a diagnosis on its own, but it raises the case for resistance training, protein, and clinical workup of underlying disease.

A low myostatin result in a healthy adult is usually benign and may reflect higher muscle mass, recent heavy training, good vitamin D status, or a partial mutation in MSTN. Very low values combined with rapidly growing muscle would justify a clinician conversation about cardiac, tendon, and metabolic checks.

The follistatin-to-myostatin ratio adds context. A ratio that has fallen over six months in someone losing weight on a GLP-1 drug is a useful signal to add resistance training and check protein intake. A stable ratio in a 70-year-old who lifts is reassuring.

For the muscle-growth strategy side of this, see reduce myostatin naturally and natural myostatin inhibitor options.

Who should bother testing

The honest list is short.

• Adults on GLP-1 agonists who want to track lean-mass risk during weight loss
• Older adults with documented sarcopenia or strong family history
• Patients with chronic kidney disease, heart failure, or cirrhosis, where myostatin sits inside the disease biology
• Anyone in a clinical trial of an anti-myostatin or anti-activin drug
• Athletes or coaches running structured before-after experiments with the same assay

The wrong fits are also worth naming.

• Healthy younger lifters chasing a number that will not change their training plan
• Anyone who plans to act on a single result without retesting on the same assay
• Patients hoping a high or low value will explain why their physique looks the way it looks
• Buyers of unapproved compounds hoping the number will validate dosing

For most readers, the highest-value test is grip strength, gait speed, and a DEXA, not a blood ELISA. Those measure what myostatin is supposed to predict.

What competitor pages overstate

Three claims show up repeatedly and deserve a sanity check.

1. "The test reveals your true muscle-building potential." It reveals a TGF-beta family protein concentration. The link to outcomes is real but indirect.
2. "Lowering this number means you will build more muscle." Lowering it through training and protein helps. Lowering it through an unregulated compound is a separate question with separate risks.
3. "One reading is enough." Assays vary, biology fluctuates seasonally, and a single number on a single day is rarely worth acting on. Trend data on the same assay is what matters.

Watching for those three sentences makes most testing-page sales copy easy to read.

Sources and notes

This article was built from DuckDuckGo and Bing SERP review, direct competitor reads, and the underlying clinical literature:

• Physicians Lab launches at-home myostatin and follistatin test — PR Newswire, March 2024
• New at-home lab test monitors muscle development — CLP Magazine
• BodyLogic Labs — Myostatin Testing
• BPS Bioscience Myostatin Assay Services
• Fulgent Genetics — Myostatin-Related Muscle Hypertrophy (MSTN gene test)
• PlexusDx Precision Peptide Genetic Test — MSTN context
• Blood myostatin levels and kidney function — Shimane CoHRE Study, PMC4621051
• Endocrine and clinical correlates of myostatin (STRAMBO) — JCEM, 2012

Frequently Asked Questions